|4.||Hypertension (High Blood Pressure)
|1.||Hiatt, William R: 29 articles (06/2015 - 01/2002)|
|2.||Criqui, Michael H: 26 articles (04/2015 - 02/2003)|
|3.||Morishita, Ryuichi: 23 articles (10/2012 - 09/2002)|
|4.||Creager, Mark A: 22 articles (01/2015 - 01/2003)|
|5.||McDermott, Mary M: 20 articles (05/2014 - 10/2005)|
|6.||Jaff, Michael R: 18 articles (10/2015 - 11/2002)|
|7.||Minar, Erich: 18 articles (04/2015 - 02/2002)|
|8.||Zeller, Thomas: 17 articles (10/2015 - 10/2009)|
|9.||Annex, Brian H: 17 articles (01/2015 - 06/2003)|
|10.||Ferrucci, Luigi: 17 articles (02/2014 - 05/2004)|
|1.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
11/01/2010 - "[The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients]."
10/01/2009 - "Efficacy of aspirin for secondary prevention in patients with peripheral artery disease."
04/01/2007 - "The efficacy of aspirin in peripheral arterial disease: an unresolved question."
06/01/2014 - "This study was designed to determine the prevalence of platelet nonresponsiveness to aspirin using point of care testing in a population with symptomatic peripheral arterial disease (PAD). "
12/01/2009 - "We also review the studies that explore this phenomenon in patients with peripheral arterial disease and discuss the optimal management options in aspirin-resistant individuals. "
|2.||clopidogrel (Plavix)FDA Link
11/01/2004 - "Clopidogrel may be especially effective in patients with peripheral arterial disease. "
10/01/2004 - "For the MI and peripheral arterial disease subgroups, clopidogrel would be considered cost-effective for a treatment duration of 2 years. "
08/01/1999 - "Clopidogrel is an effective new antiplatelet agent useful for the treatment of ischemic cerebrovascular, cardiac, and peripheral arterial disease. "
01/28/2014 - "The aim of this randomized placebo-controlled trial was to determine if withdrawing clopidogrel therapy leads to increased platelet activity compared with pre-treatment values in patients with stable coronary artery or peripheral arterial disease. "
04/01/2003 - "The aim of this study was to establish if a loading dose of clopidogrel inhibits platelet activation in patients with peripheral arterial disease (PAD). "
|3.||Carnitine (L-Carnitine)FDA LinkGeneric
12/01/1999 - "The aim of the study was to evaluate the accuracy of Doppler continuous wave, Treadmill test and 31Phosphorus magnetic resonance spectroscopy in determining the efficacy of propionyl-L-carnitine in patients with peripheral arterial disease. "
07/01/1997 - "Carnitine derivatives, such as propionyl-l-carnitine (PLC), have been shown to improve walking distance in patients with obstructive peripheral artery disease (PAOD). "
09/01/1995 - "The efficacy of propionyl-L-carnitine in increasing walking capacity in patients with peripheral arterial disease is primarily due to the metabolic effect of the drug, but a direct vasoactive action is also hypothesized. "
02/01/2013 - "Propionyl-L-carnitine (PLC) may improve exercise performance in patients with peripheral artery disease, but results from clinical trials have been inconsistent. "
11/01/2000 - "PLC is currently under investigation for the treatment of peripheral artery disease, and the present study was conducted to assess the pharmacokinetics of intravenous propionyl-L-carnitine hydrochloride. "
|4.||cilostazol (Pletal)FDA LinkGeneric
02/01/2006 - "Cilostazol has been shown in multiple randomized clinical trials to result in decreased claudication and improved ability to walk in patients with peripheral arterial disease. "
12/01/2008 - "The main aim of this study was to assess the effects of cilostazol on neuropathic symptomatology in diabetic patients with peripheral arterial disease (PAD). "
02/01/2008 - "Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects)."
09/01/2015 - "Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease."
02/01/2015 - "We analyzed 25 patients with demonstrated lower limb peripheral arterial disease to determine whether lipid peroxidation (LPO) or total antioxidant capacity (TAC) were modified after 6 months of cilostazol treatment (postintervention phase) with respect to the basal phase. "
04/01/2008 - "Nitinol self-expanding stents are effective in treating peripheral artery disease, including the superficial femoral, carotid, and renal arteries. "
12/01/2013 - "The outcome of the SUMMIT registry demonstrates that the EPIC self-expanding nitinol vascular stent is a safe and effective device for treating peripheral artery disease in the femoropopliteal segment."
10/09/2012 - "The purpose of this study is to compare post-dilation strategies of nitinol self-expanding stents implanted in the superficial femoral artery of diabetic patients with peripheral arterial disease. "
09/01/2007 - "The Zilver-PTX is a prospective multicenter randomized trial of bare metal versus drug-eluting nitinol stents for superficial femoral artery peripheral arterial disease. "
05/01/2007 - "Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease."
|6.||Idiopathic pulmonary hypertensionIBA
01/01/2009 - "Supplementation with exogenous BH4 or therapeutic approaches that increase endogenous amounts of BH4 can reduce or reverse endothelial dysfunction by restoring production of NO. Improvements in formulations of BH4 for oral delivery have stimulated clinical trials that test the efficacy of BH4 in the treatment of systemic hypertension, peripheral arterial disease, coronary artery disease, pulmonary arterial hypertension, and sickle cell disease. "
04/01/2012 - "Highly significant associations have been described between RDW value and all-cause, non-cardiac and cardiac mortality in patients with coronary artery disease, acute and chronic heart failure, peripheral artery disease, stroke, pulmonary embolism and pulmonary arterial hypertension. "
01/01/2002 - "Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension."
03/06/2009 - "Beraprost sodium, an orally active prostacyclin analogue, has proved to be beneficial for the patients with primary pulmonary hypertension and obstructive peripheral arterial disease. "
09/19/2003 - "Beraprost sodium (BPS), an orally active prostacyclin analogue, has been reported to be beneficial in the treatment of primary pulmonary hypertension and obstructive peripheral arterial disease. "
|7.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/07/2005 - "Clinical trials have recently begun on using VEGF-activating ZFPs to treat human peripheral arterial disease, by stimulating vascular growth. "
10/21/2003 - "The Regional Angiogenesis with Vascular Endothelial growth factor (RAVE) trial is the first major randomized study of adenoviral vascular endothelial growth factor (VEGF) gene transfer for the treatment of peripheral artery disease (PAD). "
06/01/2003 - "Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial."
02/01/2003 - "The first human gene therapy trial for a blood-vessel disorder was performed successfully, in which copies of an angiogenic gene, the vascular endothelial growth factor (VEGF) gene, were directly delivered to the area surrounding the diseased artery of the leg of a patient with peripheral artery disease. "
08/14/2001 - "Vascular endothelial growth factor (VEGF) currently is being evaluated in clinical angiogenesis trials involving patients with peripheral arterial disease. "
|8.||glucuronyl glucosamine glycan sulfate (Vessel)IBA
01/01/2013 - "The information in this study has implications for the therapeutic treatment of injured muscle and disorders that result in vessel occlusion, including peripheral artery disease."
06/01/1989 - "The authors used noninvasive techniques, including flow velocity by Doppler ultrasound, to accurately assess and distinguish between large and small vessel peripheral arterial disease in a population study in southern California, 1978-1981. "
01/01/1985 - "The aim of this study was the evaluation of some hemorheological and metabolic parameters in a group of patients affected by peripheral artery disease treated with sulodexide. "
11/01/2015 - "Independent factors associated with CP were the use of rotablation, intravascular ultrasound-guided PCI, bypass PCI, a totally occluded vessel, a type C lesion, peripheral arterial disease, and body mass index <25. "
07/01/2013 - "Peripheral vessel function and fracture severity may have a limited independent influence on mobility outcome after ankle fracture in those patients who do not have established pre-injury peripheral arterial disease. "
|9.||Ticlopidine (Ticlid)FDA LinkGeneric
11/01/2000 - "In peripheral arterial disease, the Swedish Ticlopidine Multicentre Study (STIMS) showed that ticlopidine was very effective against placebo. "
07/01/2002 - "Ticlopidine, an inhibitor of platelet aggregation, is widely used for peripheral arterial disease. "
07/11/1996 - "Here, we report for the first time that in patients with peripheral arterial disease and in cats with extracorporal circulation ticlopidine evokes instantaneous thrombolytic or fibrinolytic effects which are not associated with inhibition of platelet aggregation. "
01/01/1994 - "Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease."
01/01/1992 - "A double-blind, placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease in Argentina. "
06/01/2011 - "Activating peripheral arterial disease patients to reduce cholesterol: a randomized trial."
04/01/2015 - "Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterol-lowering medications alone in patients with peripheral artery disease."
12/01/2011 - "Gender differences in cholesterol-lowering medication prescribing in peripheral artery disease."
04/01/2011 - "We compared the dietary intake of participants with peripheral artery disease (PAD) and claudication with diet recommendations of the National Cholesterol Education Program (NCEP) and dietary reference intake values recommended by the Institute of Medicine (IOM) of the National Academy of Sciences. "
04/01/2010 - "Attitudes and behavior of peripheral arterial disease patients toward influencing their physician's prescription of cholesterol-lowering medication."
05/01/2015 - "On the basis of the high primary patency rate, absence of stent fracture, and significant improvements in functional and quality-of-life measures, the Supera stent provides safe and effective treatment of femoropopliteal lesions in symptomatic patients with peripheral artery disease. "
10/01/2012 - "To evaluate the clinical efficacy of EverFlex stents (length, 6-20 cm) for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA). "
09/01/2012 - "The stent aims to provide improved treatment for patients with symptomatic peripheral arterial disease in the above-the-knee femoropopliteal arteries. "
03/17/2015 - "Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study."
03/20/2013 - "Over the last decade, a myriad of small clinical studies using a wide variety drug coated balloons (DCB) has shown the potential efficacy profile of this technology in specific clinical settings, especially coronary in-stent restenosis and peripheral artery disease. "
|2.||Angioplasty (Angioplasty, Transluminal)
04/01/2007 - "Percutaneous transluminal angioplasty is feasible and effective in patients on chronic dialysis with severe peripheral artery disease."
04/01/2013 - "To assess with dynamic contrast-enhanced ultrasound (CEUS) and transient arterial occlusion whether the muscular micro-perfusion in patients with peripheral arterial disease (PAD) is improved after angioplasty or surgery. "
02/03/2015 - "Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial."
08/01/2014 - "Results of previous studies comparing bypass surgery and percutaneous transluminal angioplasty in peripheral artery disease are ambiguous. "
06/01/2014 - "The purpose of this study was to investigate the safety and feasibility of percutaneous PVS-10200 delivery after angioplasty and stenting in the SFA of patients with peripheral artery disease. "
03/01/1994 - "An intention-to-treat analysis revealed (1) the number of patients seen for peripheral arterial disease has increased steadily; (2) in the last year more were initially treated with intervention as the primary modality; (3) the results of such catheter-based procedures improved only slightly over this 5-year period, despite our learning curve and the fact that we discarded several ineffective interventional approaches; (4) the fraction of patients primarily operated on and the excellent results of surgery have not changed; and (5) the number of operations for proximal (aortoiliac) disease has decreased markedly, with a corresponding increase in distal reconstructions. "
12/01/2004 - "Advances in catheter technology, gene identification, and cell biology may provide novel treatment options for patients with peripheral arterial disease (PAD) who are not candidates for standard revascularization procedures. "
01/01/2012 - "Efficacy of metal tip catheter for chronic total occlusion lesions in peripheral arterial disease."
12/01/2007 - "Results of the multicenter first-in-man study of a novel scoring balloon catheter for the treatment of infra-popliteal peripheral arterial disease."
11/01/2005 - "The aim of this study was to determine the concordance between CTA and catheter arteriography (CA) in patients with peripheral arterial disease (PAD). "
07/01/2009 - "Platelet inhibition following coronary intervention is associated with a significantly reduced risk of graft occlusion, and has been acknowledged to be safe and effective in patients with peripheral arterial disease. "
07/01/2014 - "The aim of this study was to obtain the long-term outcomes of precuffed ePTFE grafts compared with autologous saphenous vein (ASV) grafts used in patients with peripheral arterial disease (PAD). "
08/01/2014 - "Clinical experience for peripheral arterial disease treatment shows poor results when synthetic grafts are used to approach infrapopliteal arterial segments. "
07/01/2014 - "Even when controlling for anatomic differences and degree of peripheral arterial disease, black race remained independently associated with early graft failure after infrainguinal bypass. "
05/01/2014 - "Further research is warranted to determine an optimal period of abstinence among smokers with peripheral arterial disease to reduce their risk for early graft failure."
12/01/2014 - "Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease."
08/01/2015 - "Approximately 60% were transtibial amputations PNC use reduced postoperative opioid consumption (standardised mean difference: -0.59, 95% CI -1.10 to -0.07, p = .03), maintained on sensitivity analysis for large (p = .03) and high-quality (p = .003) studies, but was marginally lost (p = .06) on studies enrolling patients with peripheral arterial disease only. "
07/01/2015 - "Trends in Major Lower Limb Amputation Related to Peripheral Arterial Disease in Hungary: A Nationwide Study (2004-2012)."
02/01/2015 - "The purpose of this study was to examine trends in racial and gender disparities in the severity of lower extremity amputation among individuals with peripheral artery disease (PAD) over the period of a decade (2002-2011). "
06/01/2014 - "The aim of this study was to describe prevalence of alcohol misuse and smoking among individuals with amputations as a result of peripheral arterial disease before surgery and 12 mos after surgery, changes in these behaviors over time, and factors associated with change. "